Robert Sikorski

Acting Chief Medical Officer at Indapta Therapeutics

Dr. Sikorski has extensive drug development experience, having most recently served as Chief Medical Officer at FivePrime Therapeutics, a public biotechnology company, where he led the development of a biologics pipeline that spanned preclinical discovery through proof of concept to pivotal trials. Previously, he led an early-stage clinical development group at Medimmune/AstraZeneca that advanced six novel molecules into clinical trials. He played a leading role in building Medimmune/AstraZeneca’s oncology portfolio through corporate partnering and acquisition efforts. Earlier in his career, he led late-stage clinical development and post marketing efforts for several commercial drugs and drug candidates at Amgen. He began his career as a Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate Harold Varmus. Dr. Sikorski has served as an editor for Science and the Journal of the American Medical Association.

Location

South San Francisco, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


Indapta Therapeutics

1 followers

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer.


Industries

Employees

11-50

Links